GRM2 and schizophrenia: LY2140023 as an mGluR2/3 agonist was originally found to have significant antipsychotic effects in patients with schizophrenia early in disease or in those previously treated with D2 drugs (83), but investigators terminated another study because LY2140023 failed to achieve significant effects on the overall symptoms of schizophrenia (Table 2).